Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease
- PMID: 18391678
- DOI: 10.1097/RHU.0b013e31816b4487
Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease
Abstract
Wegener granulomatosis is an autoimmune disorder with a double spectrum. Vasculitic manifestations are at one end of it, whereas granulomatous ones are at the other. Rituximab (RTX) is a chimeric monoclonal antibody that has been successfully used in this condition. However, the granulomatous forms have been reported to show a tendency to be less responsive to RTX than the vasculitic disease. We present 4 cases of predominantly Wegener granulomatosis that responded positively to RTX.
Comment in
-
Rituximab and antineutrophil cytoplasmic antibody-associated vasculitis: granulomatous disease more resistant than vasculitis disease?J Clin Rheumatol. 2008 Apr;14(2):61-4. doi: 10.1097/RHU.0b013e31816b449e. J Clin Rheumatol. 2008. PMID: 18391671 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
